IL13RA2 and glioblastoma: Tandem and trivalent CAR T cells have been developed in an attempt to overcome the issue of antigen loss post CAR T cell therapies that has been seen with both EGFRvIII CAR T cell therapy in patients with GBM (15) and IL13Rα2 CAR T cell therapy in a xenograft GBM mouse model (48).